Melanoma is one of the most aggressive forms of skin cancer, largely because of its ability to grow quickly and spread to other parts of the body. In this 2026 study, researchers investigated how cannabidiol (CBD) affects melanoma development by examining molecular pathways that control cancer cell growth and survival. Using laboratory experiments and animal models, scientists explored how CBD interacts with cellular signaling systems involved in tumor progression and gene regulation.

The researchers found that CBD demonstrated strong antitumor activity, reducing melanoma cell growth, limiting invasive behavior, and promoting programmed cancer cell death. A key discovery was that CBD activated the PPARγ receptor, which formed a complex with the enzyme TET1 to alter DNA methylation—a process that determines whether certain genes are turned on or off. This interaction led to demethylation and activation of the LRSAM1 gene, a tumor-suppressing pathway that helped slow melanoma progression and reduce metastatic potential in experimental models.

Although these findings come from preclinical research rather than human clinical trials, the study provides important insight into how CBD may influence cancer biology through epigenetic regulation rather than a single drug target. The authors emphasize that further research, including clinical studies in humans, is needed to determine safety, effective dosing, and whether these mechanisms translate into real-world therapeutic applications.

Source

Zhang X, et al. Cannabidiol inhibits melanoma progression by regulating PPARγ-TET1 complex-dependent LRSAM1 demethylation. Phytomedicine. 2026;151:157775. National Library of Medicine (NIH):
https://pubmed.ncbi.nlm.nih.gov/41547069/